Beyond Surgery: Bladder Preservation and the Role of Systemic Treatment in Localised Muscle-invasive Bladder Cancer

Overview

Journal World J Urol

Specialty Urology

Date 2024 Apr 4

PMID 38573431

Authors

Martin Swinton

Aarani Devi

Yee Pei Song

Peter Hoskin

Ananya Choudhury

Affiliations

Soon will be listed here.

Abstract

Over the last two to three decades the non-surgical curative management of bladder cancer has significantly progressed. Increasing evidence supports the use of bladder preservation as an alternative to radical cystectomy (RC) for localised muscle-invasive bladder cancer (MIBC). Radiosensitisation with chemotherapy or hypoxia modification improves the efficacy of radiotherapy. Systemic treatments play an important role in the management of localised MIBC with the benefit of neoadjuvant chemotherapy prior to radical treatment well established. The use of immune checkpoint inhibitors (ICIs) in the radical treatment of bladder cancer, their safe combination with radical radiotherapy regimens and whether the addition of ICIs improve rates of cure are outstanding questions beginning to be answered by ongoing clinical trials. In this narrative review, we discuss the current evidence for bladder preservation and the role of systemic treatments for localised MIBC.

Citing Articles

A balanced perspective on bladder preservation and systemic treatment in muscle-invasive bladder cancer.

Lin F, Wang L, Xu Z World J Urol. 2024; 42(1):288.

PMID: 38700672 DOI: 10.1007/s00345-024-05010-4.

References

Kong V, Hansen V, Hafeez S . Image-guided Adaptive Radiotherapy for Bladder Cancer. Clin Oncol (R Coll Radiol). 2021; 33(6):350-368. DOI: 10.1016/j.clon.2021.03.023. View

Spigel D, Faivre-Finn C, Gray J, Vicente D, Planchard D, Paz-Ares L . Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2022; 40(12):1301-1311. PMC: 9015199. DOI: 10.1200/JCO.21.01308. View

Coen J, Zhang P, Saylor P, Lee C, Wu C, Parker W . Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial. J Clin Oncol. 2018; 37(1):44-51. PMC: 6354769. DOI: 10.1200/JCO.18.00537. View

Horsman M . Nicotinamide and other benzamide analogs as agents for overcoming hypoxic cell radiation resistance in tumours. A review. Acta Oncol. 1995; 34(5):571-87. DOI: 10.3109/02841869509094031. View

Caffo O, Thompson C, De Santis M, Kragelj B, Hamstra D, Azria D . Concurrent gemcitabine and radiotherapy for the treatment of muscle-invasive bladder cancer: A pooled individual data analysis of eight phase I-II trials. Radiother Oncol. 2016; 121(2):193-198. DOI: 10.1016/j.radonc.2016.09.006. View

Paramasivan S, Huddart R, Hall E, Lewis R, Birtle A, Donovan J . Key issues in recruitment to randomised controlled trials with very different interventions: a qualitative investigation of recruitment to the SPARE trial (CRUK/07/011). Trials. 2011; 12:78. PMC: 3068963. DOI: 10.1186/1745-6215-12-78. View

Huddart R, Birtle A, Maynard L, Beresford M, Blazeby J, Donovan J . Clinical and patient-reported outcomes of SPARE - a randomised feasibility study of selective bladder preservation versus radical cystectomy. BJU Int. 2017; 120(5):639-650. PMC: 5655733. DOI: 10.1111/bju.13900. View

Sherry A, Stewart A, Luo G, Kirschner A . Intensity-Modulated Radiotherapy is Superior to Three-Dimensional Conformal Radiotherapy in the Trimodality Management of Muscle-Invasive Bladder Cancer with Daily Cone Beam Computed Tomography Optimization. J Radiat Oncol. 2020; 8(4):395-403. PMC: 7747671. DOI: 10.1007/s13566-019-00411-0. View

Tree A, Jones K, Hafeez S, Taghavi Azar Sharabiani M, Harrington K, Lalondrelle S . Dose-limiting Urinary Toxicity With Pembrolizumab Combined With Weekly Hypofractionated Radiation Therapy in Bladder Cancer. Int J Radiat Oncol Biol Phys. 2018; 101(5):1168-1171. DOI: 10.1016/j.ijrobp.2018.04.070. View

10.

Song Y, Mistry H, Irlam J, Valentine H, Yang L, Lane B . Long-Term Outcomes of Radical Radiation Therapy with Hypoxia Modification with Biomarker Discovery for Stratification: 10-Year Update of the BCON (Bladder Carbogen Nicotinamide) Phase 3 Randomized Trial (ISRCTN45938399). Int J Radiat Oncol Biol Phys. 2021; 110(5):1407-1415. DOI: 10.1016/j.ijrobp.2021.03.001. View

11.

Lawrentschuk N, Colombo R, Hakenberg O, Lerner S, Mansson W, Sagalowsky A . Prevention and management of complications following radical cystectomy for bladder cancer. Eur Urol. 2010; 57(6):983-1001. DOI: 10.1016/j.eururo.2010.02.024. View

12.

Softness K, Kaul S, Fleishman A, Efstathiou J, Bellmunt J, Kim S . Radical cystectomy versus trimodality therapy for muscle-invasive urothelial carcinoma of the bladder. Urol Oncol. 2022; 40(6):272.e1-272.e9. DOI: 10.1016/j.urolonc.2021.12.015. View

13.

Zlotta A, Ballas L, Niemierko A, Lajkosz K, Kuk C, Miranda G . Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis. Lancet Oncol. 2023; 24(6):669-681. DOI: 10.1016/S1470-2045(23)00170-5. View

14.

Powles T, Duran I, van der Heijden M, Loriot Y, Vogelzang N, De Giorgi U . Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2017; 391(10122):748-757. DOI: 10.1016/S0140-6736(17)33297-X. View

15.

de Ruiter B, van Hattum J, Lipman D, de Reijke T, Jeroen A van Moorselaar R, van Gennep E . Phase 1 Study of Chemoradiotherapy Combined with Nivolumab ± Ipilimumab for the Curative Treatment of Muscle-invasive Bladder Cancer. Eur Urol. 2022; 82(5):518-526. DOI: 10.1016/j.eururo.2022.07.009. View

16.

Choudhury A, Porta N, Hall E, Song Y, Owen R, Mackay R . Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials. Lancet Oncol. 2021; 22(2):246-255. PMC: 7851111. DOI: 10.1016/S1470-2045(20)30607-0. View

17.

Marcq G, Souhami L, Cury F, Salimi A, Aprikian A, Tanguay S . Phase 1 Trial of Atezolizumab Plus Trimodal Therapy in Patients With Localized Muscle-Invasive Bladder Cancer. Int J Radiat Oncol Biol Phys. 2021; 110(3):738-741. DOI: 10.1016/j.ijrobp.2020.12.033. View

18.

Lewis S, Murthy V, Mahantshetty U, Shrivastava S . Incidental Dose to Pelvic Nodes in Bladder-Only Radiotherapy: Is It Clinically Relevant?. Technol Cancer Res Treat. 2017; 16(3):382-387. PMC: 5616055. DOI: 10.1177/1533034617691409. View

19.

Mak R, Hunt D, Shipley W, Efstathiou J, Tester W, Hagan M . Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol. 2014; 32(34):3801-9. PMC: 4239302. DOI: 10.1200/JCO.2014.57.5548. View

20.

Flaig T, Tangen C, Daneshmand S, Alva A, Lerner S, Lucia M . A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695). Clin Cancer Res. 2021; 27(9):2435-2441. PMC: 8219246. DOI: 10.1158/1078-0432.CCR-20-2409. View